Takeda Pharmaceutical Co. Ltd. and its wholly-owned subsidiary Millennium, The Takeda Oncology Co., initiated a Phase II trial of TAK-700 in patients with advanced prostate cancer. TAK-700 is a non-steroidal androgen synthesis inhibitor that has been shown to bind to and inhibit the enzyme 17, 20 lyase1, suppressing the production of androgen. The open-label, multiple-dose study will examine the safety and efficacy of TAK-700 in patients with chemotherapy-naïve metastatic castration-resistant...